Bellicum Pharmaceuticals (NASDAQ:BLCM) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Bellicum Pharmaceuticals Trading Down 6.6 %

Shares of BLCM opened at $0.07 on Tuesday. Bellicum Pharmaceuticals has a 52 week low of $0.06 and a 52 week high of $1.31. The stock has a fifty day moving average of $0.08 and a 200-day moving average of $0.14.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bellicum Pharmaceuticals stock. HRT Financial LP bought a new position in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 36,470 shares of the biopharmaceutical company’s stock, valued at approximately $26,000. HRT Financial LP owned about 0.42% of Bellicum Pharmaceuticals as of its most recent SEC filing. 4.93% of the stock is currently owned by institutional investors.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen.